Editorial: Endothelin receptor antagonists in the treatment of prostate cancer

Prostate

Volumn 49, Issue 2, 2001, Pages 91-92

  Nelson, Joel B ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATRASENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; G PROTEIN COUPLED RECEPTOR; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC AGENT; ENDOTHELIN RECEPTOR; PYRROLIDINE DERIVATIVE;

BONE REMODELING; CANCER GROWTH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EDITORIAL; HUMAN; MULTICENTER STUDY; OSTEOCLAST; OSTEOLYSIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; BONE TUMOR; DISEASE COURSE; DRUG ANTAGONISM; MALE; METABOLISM; METASTASIS; PROSTATE TUMOR;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BONE RESORPTION; DISEASE PROGRESSION; HUMANS; MALE; PROSTATIC NEOPLASMS; PYRROLIDINES; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ENDOTHELIN;

EID: 0035488940     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.1121     Document Type: Editorial

References (12)

1. A novel potent vasoconstrictor peptide produced by vascular endothelial cells
2. Sarafotoxins and endothelins: Evolution, structure, and function
3. Endothelins: Molecular biology, biochemistry, pharmacology, physiology, and pathophysiology
4. Endothelin-1 in the human prostate: Tissue levels, source of production and isometric tension studies
5. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate
6. New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade
7. A-selective receptor antagonist
8. ABT-627, endothelin-receptor antagonist, for advanced prostate cancer: Phase I pharmacokinetic results
9. Phase I clinical results of ABT-627, an endothelin receptor antagonist, for refractory adenocarcinoma
10. Preliminary phase II results using ABT-627, an endothelin-A selective receptor antagonist, in men with symptomatic hormone-refractory prostate cancer
11. The endothelin-A receptor antagonist atrasentan (ABT-627) dealys clinical progression in hormone-refractory prostate cancer; a multinational, randomized, double-blind, placebo-controlled trial
12. The endothelin-A receptor antagonist atrasentan (ABT-627) reduces skeletal remodeling activity in men with advanced, hormone-refractory prostate cancer